Background: Central nervous system (CNS) relapse is an uncommon but challenging complication in patients with mantle cell lymphoma (MCL). Survival after CNS relapse is extremely poor. Identification of high-risk populations is therefore critical in determining patients who might be candidates for a prophylactic approach.
Results: None of the patients received intrathecal prophylaxis. Overall, 33 patients (5.4%) experienced CNS relapse during a median follow-up of 42.7 months. Median time from diagnosis to CNS relapse was 20.3 months (range: 2.2-141.3 months). Three-year cumulative incidence of CNS relapse was 5.6% [95% confidence interval (95% CI) 3.7% to 8.0%]. Univariate analysis revealed several risk factors including blastoid variant, leukemic presentation, high-risk MCL International Prognostic Index and high Ki-67 ( proliferation marker). Multivariate analyses revealed that Ki-67 ≥ 30 was the only significant risk factor for CNS relapse (hazard ratio: 6.0, 95% CI 1.9-19.4, P = 0.003). Two-year cumulative incidence of CNS relapse in patients with Ki-67 ≥ 30 was 25.4% (95% CI 13.5-39.1), while that in the patients with Ki-67 < 30 was 1.6% (95% CI 0. 4-4.2) . None of the treatment modalities, including rituximab, high-dose cytarabine, high-dose methotrexate or consolidative autologous stem-cell transplant, were associated with a lower incidence of CNS relapse. Survival after CNS relapse was poor, with median survival time of 8.3 months. There was no significant difference in the survival by the site of CNS involvement. Key words: mantle cell lymphoma, CNS relapse, risk factors, introduction Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma which is characterized by the overexpression of cyclin D1 derived from t(11;14)(q13;q32) translocation [1] . Population-based cancer registry data suggest that although the incidence of MCL appears to be increasing, it is still rare, accounting for only 2%-3% of all lymphomas [2] . Median age at diagnosis is around 70 years, with high male predominance. Despite recent data suggesting that survival is improving, MCL remains essentially incurable with conventional chemotherapy, with a median survival of 5-7 years [3] .
Central nervous system (CNS) relapse is an uncommon but challenging complication in patients with MCL. The role of CNS prophylaxis in this disease remains unclear, and neither the National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline in Oncology nor European Society of Medical Oncology (ESMO) provides recommendations on CNS prophylaxis [4] . However, survival after CNS relapse is extremely poor [5] [6] [7] , and identification of high-risk populations is critical to identifying candidates for possible prophylaxis. However, the few studies of risk factors for CNS relapse were relatively small in size and with limited variables [5] [6] [7] .
Here, to better understand the incidence of CNS relapse in patients with MCL and evaluate risk factors and outcomes, we conducted a retrospective analysis in a large cohort of patients.
patients and methods patients A total of 633 consecutive patients newly diagnosed with MCL between 1992 and 2012 at 63 institutions in Japan were retrospectively reviewed. Diagnosis of MCL was confirmed by the typical morphology and immunohistochemistry of cyclin D1 or detection of IgH/CCND1 translocation by fluorescence in situ hybridization at each institution. Diagnosis was further confirmed by central review by two hematopathologists (NA and SN) using pathological specimens, which were available for 425 cases (67%), in accordance with the 2008 WHO classification [1] . Ki-67 (ab15580, abcam) and SOX11 (S8068, Sigma Life Science) were stained using available unstained slides by a uniform technique at pathology department laboratory in Nagoya University and evaluated at central review. After exclusion of 17 patients (2.7%) due to an unconfirmed diagnosis of MCL (6 patients) or insufficient follow-up or lack of important clinical data (11 patients), 616 patients were identified. Eight patients [1.3%, 95% confidence interval (95% CI) 0.6% to 2.5%] were then excluded since they had evidence of CNS involvement at initial diagnosis, leaving 608 patients for final analysis. The study was carried out in accordance with the Declaration of Helsinki and was approved by the institutional review board of Nagoya University School of Medicine.
treatment
Patients were treated according to the standard protocols of the participating institutions. Those who received a high-dose cytarabine-containing regimen (HDAC), including R ± hyper-CVAD/R-MA [8] and R ± CHASE (cyclophosphamide, cytarabine, etoposide, dexamethasone and rituximab) [9] regimens, were grouped together. Those who received chemotherapy other than CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) or HDAC, such as fludarabine-based chemotherapy or rituximab monotherapy, were grouped together as the 'Others' treatment group.
statistical analysis
Time to CNS relapse was calculated from the date of initial diagnosis of lymphoma to the date of CNS relapse, as confirmed by imaging studies or cytology with CSF. Cumulative incidence of CNS relapse was calculated by competing risk regression (CRR) analysis as described elsewhere in detail [10] . In this analysis, death without CNS relapse was defined as the competing event.
Patient characteristics were analyzed for their association with time to CNS relapse using CRR based on Fine and Gray's sub-hazard ratios (HRs) with 95% confidence interval (95% CI) as measures of association [11] . The multivariate analyses were conducted using characteristics which were significant in the univariate analyses. Since the patients received various treatments, chemotherapy regimen was adjusted as a confounder in the multivariate analysis. Overall survival (OS) from CNS relapse was calculated from the diagnosis of CNS relapse to death from any cause using the Kaplan-Meier method.
Calculation, scoring and separation of risk groups in the original, simplified and biological Mantle Cell Lymphoma International Prognostic Indexes (MIPI, s-MIPI and b-MIPI) were done as described previously [12] . A dummy variable was used for missing data. All analyses were carried out using STATA version 13.1 (StataCorp LP, College Station, TX), with significance set at the 5% level. and 71% had bone marrow involvement. Twenty-two percent of patients presented with a B symptom and 11% had an ECOG performance status (PS) of 2-4. Overall, 495 patients (81%) received a rituximab-containing regimen, with 328 receiving CHOP, 196 receiving HDAC and 84 receiving another regimen such as fludarabine. One hundred two patients (17%) received a consolidated autologous stem-cell transplant (ASCT). No patients received prophylactic intrathecal chemotherapy at first-line treatment. After first-line chemotherapy, 79% of patients achieved an overall response, and 53% achieved a complete response.
Among 425 patients who had pathological slides for central review, 300 could be analyzed for Ki-67. Of these, 57 patients (19%) showed a Ki-67 of 30 or higher. These patients are also characterized in Table 1 .
After a median follow-up of 42.7 months, 239 of 608 patients (39%) had died. Median PFS and OS were 24.7 and 78.5 months, respectively.
CNS relapse and risk factors
Overall, 33 patients (5.4%) experienced CNS relapse during the median follow-up of 42.7 months. Seven patients presented with a brain parenchymal mass, 18 with leptomeningeal disease and 8 with both. Median time from initial diagnosis to CNS relapse was 20.3 months (range: 2.2-141.3 months).
One-, 3-and 5-year cumulative incidence of CNS relapse was 2.3% (95% CI 1.3% to 3.8%), 5.6% (95% CI 3.7% to 8.0%) and 7.2% (95% CI 4.9% to 10.2%), respectively ( Figure 1A ). Table 2 summarizes univariate analyses for the risk factors of CNS relapse by the CRR model. Significant factors in these analyses were PS ≥ 2-4, leukemic presentation at the time of diagnosis, WBC count (10 6 /l) ≥ 15 000, serum albumin <3.5 g/dl, serum total protein <6.0 g/dl, blastoid or pleomorphic variant, Ki-67 ≥ 30 and a high-risk group in MIPI, simplified MIPI or biologic MIPI at diagnosis. No difference was seen in the incidence of CNS relapse between treatment with or without rituximab (supplementary Figure S1 , available at Annals of Oncology online, P = 0.35). Further, the decreased risk of CNS relapse was not associated with treatment with either HDAC or consolidative ASCT. Among these significant risk factors, the strongest predictive factor for CNS relapse was Ki-67 ≥ 30, and Ki-67 ≥ 30 was the only significant risk factor on multivariate analysis (HR: 6.0, 95% CI 1.9-19.4, P = 0.003) ( Table 2) . Two-year cumulative incidence of CNS relapse in patients with Ki-67 ≥ 30 was 25.4% (95% CI 13.5-39.1), versus 1.6% (Figure 2 ), while that in patients with Ki-67 < 20 and 50 was 1.7% (95% CI 0.5-4.7) and 2.3% (95% CI 0.8-5.0). Ki-67 ≥ 30 was also a significant risk factor for CNS relapse in patients who received R ± CHOP ( Figure 1C ) and R ± hyper-CVAD/MA ( Figure 1D ), with the cumulative incidence of relapse in these patients within 2 years of >25%. 
survival after CNS relapse
Thirteen patients received a high-dose methotrexate (MTX) regimen, 10 received whole-brain radiotherapy (WBRT) or radiotherapy to the spine, and 2 received both. Twenty-one patients received IT chemotherapy with MTX with or without cytarabine, of whom 7 only received IT chemotherapy for the treatment of CNS diseases because of the presence of systemic disease or poor condition. Only one patient underwent ASCT after CNS relapse. Treatment information was not available for two patients. Survival after CNS relapse was extremely poor, with a median survival time of 8.3 months (95% CI 3.8-10.2 months, Figure 3A ). Site of presentation was not associated with survival after relapse ( Figure 3B ). The survival after relapse was significantly better in patient who relapsed without CNS disease than the patient who had CNS disease (median survival 41.6 versus 8.3 months, P < 0.001).
discussion
CNS relapse is thought to be a rare event in patients with MCL, and neither the NCCN nor ESMO guidelines describe prophylactic approaches [4] . Previous studies have described a relatively low overall CNS relapse rate of 4%-8% [5, 6] , which was consistent with our results of 5.4% on a median follow-up of 42.7 months. A study by the European MCL Network identified several correlations between baseline patient characteristics and CNS relapse in 162 patients, namely blastoid histology, presence of B symptoms, elevated LDH, poor PS and high MIPI [6] . However, there was no significant correlation between Ki-67 and CNS relapse in the study. Other studies have also identified blastoid histology as a risk factor for CNS relapse [5, 7] . We validated blastoid histology and poor PS as risk factors for CNS relapse and identified several new risk factors, including leukemic presentation, high WBC count, low serum albumin or total protein. Nevertheless, none of these factors was sufficient to identify serious high-risk patient populations in MCL. However, the cumulative incidence of CNS relapse in patients with Ki-67 ≥ 20, 30 and 50 is considerably high, at 17%, 25% and 35% in 2 years. Of interest, this rate is similar to or even higher than the 2-year CNS relapse rate in patients with testicular or breast diffuse large B-cell lymphoma (DLBCL), both of which are listed as candidates for CNS prophylaxis in the NCCN guidelines [13, 14] . The proliferation signature is closely correlated with the morphological subtype of MCL and predicts survival well [15] . Proliferation activity expressed by Ki-67 is detected by immunohistochemical staining and is significantly associated with survival in MCL [16, 17] . We found that high Ki-67 is also a serious risk factor for CNS relapse. The stepwise increase in HR and cumulative incidence with Ki-67 score indicates that Ki-67 is a valid and score-dependent factor. In their small study (82 patients), Ferrer et al. showed that Ki-67 ≥50% was significantly associated with the risk of CNS relapse in patients with MCL [7] . Although it is presently difficult to precisely determine a cutoff point for this continuous variable, the cumulative incidence of CNS relapse from our results suggests that patients presenting with Ki-67 ≥ 30 are candidates for aggressive CNS prophylaxis.
Treatment with rituximab combination chemotherapy was not associated with a lower incidence of CNS relapse in MCL (supplementary Figure S1 , available at Annals of Oncology online), nor was HDAC or consolidative ASCT. Even in patients who received hyper-CVAD/MA [8] , the second part of which consists of HDAC and high-dose MTX, the incidence of CNS relapse with high Ki-67 was the same as in patients who received CHOP ( Figure 1C and D) . This indicates that the cytarabine and MTX dose schedule used in hyper-CVAD/MA does not prevent CNS relapse in very high-risk patients. Ferrer et al. also suggested that hyper-CVAD/MA offered no advantage in reducing the risk of CNS relapse [7] . In our patient cohort, none of the patients received IT prophylaxis. Recent data suggest that administration of IT chemotherapy with high-dose MTX and/or cytarabine provides some decrease in the risk of CNS relapse in DLBCL [18] . The role of IT prophylaxis is still controversial; however, the incidence of CNS relapse rate in patients who receive IT prophylaxis together with hyper-CVAD/MA would be of interest.
As described previously [5] [6] [7] , prognosis after CNS relapse is extremely poor irrespective of site of involvement. In our series, only one patient who received ASCT after CNS relapse survived more than 3 years, albeit that this number is too small to be suggestive. Considering survival outcomes from previous studies, ASCT appears to be a therapeutic goal for CNS relapse [19] , but the median age of patients with MCL is now around 70 years, and half of patients will not be suitable candidates. These limited options after CNS relapse warrants the development of new prophylactic treatment strategies for these seriously highrisk patients. Of note, all CNS relapses in patients who presented with Ki-67 ≥ 30 occurred within 2 years, and 27% were diagnosed during first-line chemotherapy. Since the MTX dose used in hyper-CVAD/MA is relatively low, at 1 g/m 2 over 24 h, it would be interesting to evaluate the effect of a higher dose, such as 3 g/m 2 over a shorter time, which yields tumoricidal levels in the cerebrospinal fluid [20] , early in the treatment cycle in highKi-67 eligible patients. Also, lenalidomide has been shown to have a role in the treatment of MCL [21, 22] ; this agent appears to penetrate the blood-brain barrier [23] , and has some impact in the treatment of CNS diseases [24, 25] . It would be interesting to evaluate the role of lenalidomide in patients who are at high risk of CNS relapse but are not eligible for high-dose MTX. Although none of our patients had CNS symptom at the time of diagnosis, it is possible that those who experienced CNS relapse early in the course of treatment also had CNS involvement at that time. Evaluation of cerebrospinal fluid and the possibility of IT prophylaxis in these high-risk patients therefore appear prudent. CNS relapse severely impairs quality of life and improving survival with an effective and targeted prophylactic approach should be investigated.
The present study was conducted under a retrospective design, and several limitations warrant mention. Patients were treated with a range of treatments in accordance with institutional standards, which might have induced bias. However, none of the patients had received IT prophylaxis, and Ki-67 remained a risk factor on stratified analysis not only in patients who did not receive CNS-penetrating drugs (CHOP and others) and also in those who did receive CNS-penetrating drugs (hyper-CVAD/ MA), indicating that Ki-67 is a strong and serious predictive factor regardless of chemotherapy regimen. Although interlaboratory variation in immunostaining and Ki-67 scoring procedures is reportedly high [26] , all Ki-67 scores in our study were calculated under central review by uniform evaluation. Further, while missing data are problematic in any retrospective analysis, we applied dummy variables to missing data and confirmed that these missing data did not skew the outcome either way. Nevertheless, our results should be validated in other studies.
In conclusion, we identified several risk factors for CNS relapse in patients with MCL. High Ki-67 is strongly associated with the risk of CNS relapse, with a 2-year cumulative incidence of CNS relapse in those who present with Ki-67 ≥ 30 of 25.4%. Patients with a high Ki-67 at diagnosis must be evaluated for CNS involvement. The development of new CNS prophylactic treatment strategies is urgently required.
acknowledgements
We thank all the participating centers and collaborators for their contribution to the collection of patient data (supplementary Appendix, available at Annals of Oncology online). We also thank the patients, physicians, nurses and staff who participated in this multicenter study. This study was conducted on behalf of the Japan Hematological Malignancy Study Group.
